Literature DB >> 31693980

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Robert J Motzer1, Eric Jonasch2, M Dror Michaelson3, Lakshminarayanan Nandagopal4, John L Gore5, Saby George6, Ajjai Alva7, Naomi Haas8, Michael R Harrison9, Elizabeth R Plimack10, Jeffrey Sosman11, Neeraj Agarwal12, Sam Bhayani13, Toni K Choueiri14, Brian A Costello15, Ithaar H Derweesh16, Thomas H Gallagher5, Steven L Hancock17, Christos Kyriakopoulos18, Chad LaGrange19, Elaine T Lam20, Clayton Lau21, Bryan Lewis22, Brandon Manley23, Brittany McCreery5, Andrew McDonald4, Amir Mortazavi24, Phillip M Pierorazio25, Lee Ponsky26, Bruce G Redman7, Bradley Somer27, Geoffrey Wile28, Mary A Dwyer, Lydia J Hammond29, Griselda Zuccarino-Catania29.   

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

Entities:  

Mesh：

Year:  2019        PMID： 31693980     DOI： 10.6004/jnccn.2019.0054

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  56 in total

1.  Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Xudong Zhu; Xingming Zhang; Guangxi Sun; Zhenhua Liu; Haoran Zhang; Yaojing Yang; Yuchao Ni; Jindong Dai; Sha Zhu; Junru Chen; Jinge Zhao; Zhipeng Wang; Hao Zeng; Pengfei Shen
Journal:  Cancer Manag Res       Date:  2021-08-31       Impact factor: 3.989

2.  Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.

Authors:  Ravi B Parikh; Eun Jeong Min; E Paul Wileyto; Fauzia Riaz; Cary P Gross; Roger B Cohen; Rebecca A Hubbard; Qi Long; Ronac Mamtani
Journal:  JAMA Oncol       Date:  2021-12-01       Impact factor: 31.777

3.  Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma.

Authors:  Lixiao Liu; Xuedan Du; Jintao Fang; Jinduo Zhao; Yong Guo; Ye Zhao; Chengyang Zou; Xiaojian Yan; Wenfeng Li
Journal:  J Inflamm Res       Date:  2021-09-27

4.  THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy.

Authors:  Oktay Halit Aktepe; Fatma Gundogdu; Kemal Kosemehmetoglu; Haci Hasan Yeter; Sercan Aksoy; Deniz Can Guven; Taha Koray Sahin; Deniz Yuce; Neyran Kertmen; Omer Dizdar; Suayib Yalcin; Mustafa Erman
Journal:  Ir J Med Sci       Date:  2021-09-01       Impact factor: 2.089

Review 5.  Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.

Authors:  Mohammad Haroon; Paul Sathiadoss; Rebecca M Hibbert; Satheesh Krishna Jeyaraj; Christopher Lim; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-07-10

6.  Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.

Authors:  Chirag Krishna; Renzo G DiNatale; Fengshen Kuo; Raghvendra M Srivastava; Lynda Vuong; Diego Chowell; Sounak Gupta; Chad Vanderbilt; Tanaya A Purohit; Ming Liu; Emily Kansler; Briana G Nixon; Ying-Bei Chen; Vladimir Makarov; Kyle A Blum; Kyrollis Attalla; Stanley Weng; Michael L Salmans; Mahdi Golkaram; Li Liu; Shile Zhang; Raakhee Vijayaraghavan; Traci Pawlowski; Victor Reuter; Maria I Carlo; Martin H Voss; Jonathan Coleman; Paul Russo; Robert J Motzer; Ming O Li; Christina S Leslie; Timothy A Chan; A Ari Hakimi
Journal:  Cancer Cell       Date:  2021-04-15       Impact factor: 31.743

Review 7.  Decision-making in active surveillance in kidney cancer: current trends and future urine and tissue markers.

Authors:  Sunil H Patel; Nirmish Singla; Phillip M Pierorazio
Journal:  World J Urol       Date:  2021-08-09       Impact factor: 4.226

8.  Small bowel obstruction caused by secondary jejunal tumor from renal cell carcinoma: A case report.

Authors:  Gao-Chen Bai; Yue Mi; Yi Song; Jin-Rui Hao; Zhi-Song He; Jie Jin
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

9.  Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.

Authors:  Yuping Zhang; Sathiya P Narayanan; Rahul Mannan; Gregory Raskind; Xiaoming Wang; Pankaj Vats; Fengyun Su; Noshad Hosseini; Xuhong Cao; Chandan Kumar-Sinha; Stephanie J Ellison; Thomas J Giordano; Todd M Morgan; Sethuramasundaram Pitchiaya; Ajjai Alva; Rohit Mehra; Marcin Cieslik; Saravana M Dhanasekaran; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-15       Impact factor: 12.779

10.  Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).

Authors:  Michael R Harrison; Brian A Costello; Nrupen A Bhavsar; Ulka Vaishampayan; Sumanta K Pal; Yousef Zakharia; Heather S L Jim; Mayer N Fishman; Ana M Molina; Christos E Kyriakopoulos; Che-Kai Tsao; Leonard J Appleman; Benjamin A Gartrell; Arif Hussain; Walter M Stadler; Neeraj Agarwal; Russell K Pachynski; Thomas E Hutson; Hans J Hammers; Christopher W Ryan; Brant A Inman; Jack Mardekian; Azah Borham; Daniel J George
Journal:  Cancer       Date:  2021-03-25       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.